A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
Minas P. Economides(NYU Langone Health), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Amishi Y. Shah(The University of Texas MD Anderson Cancer Center), Camilo Jiménez(The University of Texas MD Anderson Cancer Center), Mouhammed Amir Habra(The University of Texas MD Anderson Cancer Center), Monica Desai(Houston Methodist)
Cited by 18
Related Papers
American Association of Endocrine Surgeons Guidelines for Adrenalectomy
|JAMA Surgery|2022|224
Phase 2 study of pembrolizumab in patients with advanced rare cancers
|Journal for ImmunoTherapy of Cancer|2020|130
Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study
|Hepatology|2017|121
Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia
|Endocrine Reviews|2022|86